View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 2, 2020

Gilead initiates two studies of remdesivir for Covid-19 in UK

Gilead Sciences has launched two Phase III clinical trials of its investigational antiviral drug remdesivir in the UK to treat Covid-19 patients.

Gilead Sciences has launched two Phase III clinical trials of its investigational antiviral drug remdesivir in the UK to treat Covid-19 patients.

The two studies will be conducted at 15 sites in the country, primarily in England and Scotland.

One of the trials will involve patients with moderate symptoms and the other will enrol patients in a serious condition.

Gilead Sciences UK & Ireland vice-president and general manager Hilary Hutton-Squire said: “Gilead started research into remdesivir more than a decade ago. We are now in a position to consider its potential to treat Covid-19 and rapidly progress its development and these clinical trials will help generate important data on the safety and efficacy of the medication in the coming weeks.”

The trials are being supported by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), National Institute for Health Research (NIHR) and the Department of Health and Social Care (DHSC).

MHRA licensing division director Dr Siu Ping Lam said: “We have procedures for rapid scientific advice, reviews and approvals and are ready to support manufacturers, researchers and other regulators.

“We have dedicated resources to ensure this happens, as we did during the Ebola crisis when we authorised clinical trial applications within a week.”

Covid-19 trials of remdesivir are already underway in the US and China.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU